Regeneron Pharmaceuticals Company Profile (NASDAQ:REGN)

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals logoRegeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company's segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. It commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases. Its marketed products include EYLEA (aflibercept) injection, Praluent (alirocumab) Injection and ARCALYST (rilonacept) injection for subcutaneous use. Its other products include Sarilumab (REGN88), Dupilumab (REGN668), REGN2222, Fasinumab (REGN475), REGN2810, REGN2176-3, Evinacumab (REGN1500) and REGN1908-1909.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: REGN
  • CUSIP: 75886F10
Key Metrics:
  • Previous Close: $363.53
  • 50 Day Moving Average: $393.51
  • 200 Day Moving Average: $391.75
  • 52-Week Range: $329.09 - $592.59
  • Trailing P/E Ratio: 56.83
  • Foreward P/E Ratio: 25.19
  • P/E Growth: 1.91
  • Market Cap: $38.11B
  • Outstanding Shares: 104,633,000
  • Beta: 1.31
  • Net Margins: 15.65%
  • Return on Equity: 23.77%
  • Return on Assets: 15.35%
  • Debt-to-Equity Ratio: 0.09%
  • Current Ratio: 3.37%
  • Quick Ratio: 3.04%
Additional Links:
Companies Related to Regeneron Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) (?)
Ratings Breakdown: 1 Sell Rating, 12 Hold Ratings, 10 Buy Ratings
Consensus Rating:Hold (Score: 2.39)
Consensus Price Target: $480.81 (32.73% upside)

Analysts' Ratings History for Regeneron Pharmaceuticals (NASDAQ:REGN)
DateFirmActionRatingPrice TargetDetails
10/13/2016Piper Jaffray Cos.Set Price TargetHold$447.00View Rating Details
10/12/2016Roth CapitalReiterated RatingBuy$520.00View Rating Details
10/4/2016RBC Capital MarketsReiterated RatingOutperform$648.00View Rating Details
10/4/2016Robert W. BairdReiterated RatingNeutral$448.00View Rating Details
10/3/2016Leerink SwannSet Price TargetBuy$530.00View Rating Details
9/30/2016Canaccord GenuityReiterated RatingHold$450.00View Rating Details
9/30/2016Chardan CapitalReiterated RatingSell$325.00View Rating Details
9/27/2016Goldman Sachs Group Inc.Reiterated RatingBuy$521.00View Rating Details
8/17/2016Jefferies GroupReiterated RatingHoldView Rating Details
8/5/2016Brean CapitalReiterated RatingBuy$489.00View Rating Details
8/5/2016Cowen and CompanyReiterated RatingHold$430.00View Rating Details
7/12/2016BTIG ResearchReiterated RatingHoldView Rating Details
6/30/2016Sanford C. BernsteinReiterated RatingBuyView Rating Details
6/23/2016Citigroup Inc.Reiterated RatingBuy$470.00View Rating Details
6/8/2016Wells Fargo & Co.Reiterated RatingHoldView Rating Details
4/8/2016Morgan StanleyLower Price Target$436.00 -> $415.00View Rating Details
4/1/2016Credit Suisse Group AGReiterated RatingHold$481.00View Rating Details
3/17/2016SunTrust Banks Inc.Lower Price TargetNeutral$450.00 -> $410.00View Rating Details
3/15/2016GabelliInitiated CoverageBuy$574.00View Rating Details
3/13/2016JPMorgan Chase & Co.Reiterated RatingNeutralView Rating Details
2/11/2016Bank of America Corp.Reiterated RatingBuy$649.00 -> $525.00View Rating Details
2/10/2016Royal Bank Of CanadaReiterated RatingOutperform$676.00 -> $668.00View Rating Details
2/10/2016Barclays PLCLower Price TargetEqual Weight$610.00 -> $425.00View Rating Details
8/31/2015Raymond James Financial Inc.Initiated CoverageOutperform$615.00View Rating Details
8/6/2015ArgusBoost Price TargetBuy$560.00 -> $660.00View Rating Details
8/4/2015Deutsche Bank AGReiterated RatingBuy$650.00 -> $720.00View Rating Details
7/27/2015BMO Capital MarketsReiterated RatingMarket Perform$381.00 -> $494.00View Rating Details
7/22/2015Northland SecuritiesInitiated CoverageMarket Perform$560.00View Rating Details
(Data available from 10/24/2014 forward)


Earnings History for Regeneron Pharmaceuticals (NASDAQ:REGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216$2.65$2.82$1.24 billion$1.21 billionViewN/AView Earnings Details
5/5/2016Q116$2.58$2.57$1.18 billion$1.20 billionViewN/AView Earnings Details
2/9/2016Q415$3.40$2.83$1.17 billion$1.10 billionViewListenView Earnings Details
11/4/2015Q315$2.62$3.47$1.05 billion$1.14 billionViewListenView Earnings Details
8/4/2015Q215$2.77$2.89$887.03 million$999.00 millionViewListenView Earnings Details
5/7/2015Q115$2.50$2.88$820.30 million$870.00 millionViewN/AView Earnings Details
2/10/2015Q414$2.78$2.79$775.42 million$802.00 millionViewN/AView Earnings Details
11/4/2014Q314$2.57$2.52$733.04 million$726.00 millionViewN/AView Earnings Details
8/5/2014Q214$2.30$2.47$647.99 million$666.00 millionViewN/AView Earnings Details
5/8/2014Q114$0.94$0.58$609.04 million$626.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.97$2.24$579.17 million$610.00 millionViewN/AView Earnings Details
11/5/2013Q313$0.92$2.40$501.93 million$597.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.92$1.73$470.63 million$458.00 millionViewN/AView Earnings Details
5/3/2013Q1 2013$1.46$1.78$424.26 million$440.00 millionViewN/AView Earnings Details
2/14/2013Q4 2012$1.11$1.47$392.64 million$415.00 millionViewN/AView Earnings Details
10/24/2012$1.14$1.89ViewN/AView Earnings Details
7/25/2012$0.45$0.90ViewN/AView Earnings Details
4/26/2012($0.33)$0.37ViewN/AView Earnings Details
2/13/2012($0.60)($0.37)ViewN/AView Earnings Details
7/28/2011($0.40)($0.69)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Regeneron Pharmaceuticals (NASDAQ:REGN)
Current Year EPS Consensus Estimate: $11.02 EPS
Next Year EPS Consensus Estimate: $14.38 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$1.47$2.49$1.98
Q2 20161$1.62$1.62$1.62
Q3 20161$1.69$1.69$1.69
Q4 20162$1.77$2.79$2.28
(Data provided by Zacks Investment Research)


Dividend History for Regeneron Pharmaceuticals (NASDAQ:REGN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Regeneron Pharmaceuticals (NASDAQ:REGN)
Insider Ownership Percentage: 10.40%
Institutional Ownership Percentage: 68.32%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/29/2016Joseph L GoldsteinDirectorSell2,125$425.00$903,125.00View SEC Filing  
6/14/2016SanofiMajor ShareholderBuy64,731$363.86$23,553,021.66View SEC Filing  
5/24/2016Arthur F RyanDirectorSell1,000$396.64$396,640.00View SEC Filing  
5/18/2016Plew Daniel P VanEVPSell4,413$385.77$1,702,403.01View SEC Filing  
4/6/2016Joseph L GoldsteinDirectorSell2,000$425.00$850,000.00View SEC Filing  
3/21/2016Joseph L GoldsteinDirectorSell2,000$375.00$750,000.00View SEC Filing  
2/17/2016SanofiMajor ShareholderBuy161,157$392.46$63,247,676.22View SEC Filing  
1/12/2016SanofiMajor ShareholderBuy83,938$465.04$39,034,527.52View SEC Filing  
12/29/2015Douglas S. MccorkleVPSell3,954$552.08$2,182,924.32View SEC Filing  
12/10/2015Michael S. BrownDirectorSell3,000$546.45$1,639,350.00View SEC Filing  
12/2/2015George YancopoulosinsiderSell43,348$549.03$23,799,352.44View SEC Filing  
11/18/2015P Roy VagelosChairmanSell17,240$587.90$10,135,396.00View SEC Filing  
11/10/2015Plew Daniel P. VanSVPSell5,123$554.85$2,842,496.55View SEC Filing  
11/9/2015Neil StahlEVPSell42,101$561.45$23,637,606.45View SEC Filing  
11/3/2015P Roy VagelosChairmanSell17,242$580.19$10,003,635.98View SEC Filing  
11/2/2015George YancopoulosinsiderSell43,348$571.61$24,778,150.28View SEC Filing  
10/6/2015SanofiMajor ShareholderBuy80,538$459.71$37,024,123.98View SEC Filing  
9/23/2015SanofiMajor ShareholderBuy147,209$534.67$78,708,236.03View SEC Filing  
9/21/2015Michael S. BrownDirectorSell3,000$551.55$1,654,650.00View SEC Filing  
9/17/2015Charles A. BakerDirectorSell5,000$550.00$2,750,000.00View SEC Filing  
8/14/2015Peter PowchikSVPSell23,485$573.38$13,465,829.30View SEC Filing  
7/15/2015Joseph L GoldsteinDirectorSell2,000$550.00$1,100,000.00View SEC Filing  
6/22/2015Joseph L GoldsteinDirectorSell2,000$526.85$1,053,700.00View SEC Filing  
5/27/2015Robert Alexander IngramDirectorSell1,379$513.39$707,964.81View SEC Filing  
5/26/2015Plew Daniel P VanSVPSell18,370$508.42$9,339,675.40View SEC Filing  
5/22/2015Douglas S MccorkleVPSell13,000$515.60$6,702,800.00View SEC Filing  
5/22/2015Joseph L GoldsteinDirectorSell4,000$514.28$2,057,120.00View SEC Filing  
5/15/2015Michael S BrownDirectorSell5,000$495.00$2,475,000.00View SEC Filing  
3/25/2015Charles A BakerDirectorSell5,000$454.96$2,274,800.00View SEC Filing  
3/24/2015Michael S AbermanSVPSell4,843$478.99$2,319,748.57View SEC Filing  
3/18/2015Michael S AbermanSVPSell3,442$465.00$1,600,530.00View SEC Filing  
3/17/2015Robert J TerifaySVPSell10,993$451.01$4,957,952.93View SEC Filing  
3/16/2015Joseph J LarosaSVPSell18,311$450.00$8,239,950.00View SEC Filing  
2/27/2015Douglas S MccorkleVPSell3,000$416.24$1,248,720.00View SEC Filing  
2/26/2015Marc Tessier-LavigneDirectorSell3,000$421.95$1,265,850.00View SEC Filing  
2/24/2015Robert J TerifaySVPSell11,173$423.67$4,733,664.91View SEC Filing  
2/23/2015Plew Daniel P VanSVPSell9,431$427.82$4,034,770.42View SEC Filing  
2/20/2015Joseph L GoldsteinDirectorSell5,000$423.65$2,118,250.00View SEC Filing  
2/17/2015Michael S AbermanSVPSell3,692$404.46$1,493,266.32View SEC Filing  
1/2/2015Leonard S SchleiferCEOSell1,500$410.58$615,870.00View SEC Filing  
1/2/2015Peter PowchikSVPSell10,822$414.08$4,481,173.76View SEC Filing  
12/24/2014SanofiMajor ShareholderBuy201,459$393.21$79,215,693.39View SEC Filing  
12/16/2014Douglas S MccorkleVPSell8,486$410.15$3,480,532.90View SEC Filing  
11/24/2014Alfred G GilmanDirectorSell40,000$408.44$16,337,600.00View SEC Filing  
11/24/2014Neil StahlSVPSell5,307$412.93$2,191,419.51View SEC Filing  
11/18/2014Robert J TerifaySVPSell22,362$405.79$9,074,275.98View SEC Filing  
11/13/2014Plew Daniel P VanSVPSell8,575$399.34$3,424,340.50View SEC Filing  
11/12/2014Joseph L GoldsteinDirectorSell5,000$398.31$1,991,550.00View SEC Filing  
11/12/2014Leonard S SchleiferCEOSell45,817$400.30$18,340,545.10View SEC Filing  
10/28/2014Leonard S SchleiferCEOSell69,112$404.01$27,921,939.12View SEC Filing  
10/24/2014Michael S BrownDirectorSell5,000$399.00$1,995,000.00View SEC Filing  
10/24/2014Murray A GoldbergSVPSell26,788$400.70$10,733,951.60View SEC Filing  
9/16/2014SanofiMajor ShareholderBuy31,717$349.26$11,077,479.42View SEC Filing  
9/15/2014SanofiMajor ShareholderBuy140,632$345.15$48,539,134.80View SEC Filing  
9/10/2014P Roy VagelosChairmanSell10,328$350.07$3,615,522.96View SEC Filing  
8/27/2014Joseph L GoldsteinDirectorSell2,000$350.31$700,620.00View SEC Filing  
8/19/2014Michael S AbermanVPSell3,611$350.00$1,263,850.00View SEC Filing  
8/18/2014Douglas S MccorkleVPSell5,875$353.00$2,073,875.00View SEC Filing  
8/15/2014Michael S BrownDirectorSell3,000$349.20$1,047,600.00View SEC Filing  
8/14/2014Joseph L GoldsteinDirectorSell2,000$347.65$695,300.00View SEC Filing  
8/13/2014P Roy VagelosChairmanSell8,028$340.01$2,729,600.28View SEC Filing  
8/11/2014Neil StahlSVPSell11,646$339.96$3,959,174.16View SEC Filing  
8/11/2014P Roy VagelosChairmanSell11,972$340.11$4,071,796.92View SEC Filing  
8/8/2014Neil StahlSVPSell2,841$340.60$967,644.60View SEC Filing  
8/7/2014Plew Daniel P VanSVPSell6,806$338.37$2,302,946.22View SEC Filing  
8/6/2014Joseph L GoldsteinDirectorSell2,000$331.20$662,400.00View SEC Filing  
7/15/2014SanofiMajor ShareholderBuy129,100$314.92$40,656,172.00View SEC Filing  
7/14/2014SanofiMajor ShareholderBuy300,000$316.80$95,040,000.00View SEC Filing  
7/10/2014SanofiMajor ShareholderBuy175,000$311.08$54,439,000.00View SEC Filing  
7/9/2014SanofiMajor ShareholderBuy348,000$309.76$107,796,480.00View SEC Filing  
7/7/2014SanofiMajor ShareholderBuy356,700$312.37$111,422,379.00View SEC Filing  
7/2/2014SanofiMajor ShareholderBuy212,400$307.25$65,259,900.00View SEC Filing  
7/1/2014SanofiMajor ShareholderBuy212,400$300.20$63,762,480.00View SEC Filing  
6/30/2014SanofiMajor ShareholderBuy262,400$281.17$73,779,008.00View SEC Filing  
5/23/2014Plew Daniel VanSVPSell5,369$295.93$1,588,848.17View SEC Filing  
5/19/2014Sanofimajor shareholderBuy190,751$300.04$57,232,930.04View SEC Filing  
3/28/2014Sanofimajor shareholderBuy306,945$306.73$94,149,239.85View SEC Filing  
3/27/2014Sanofimajor shareholderBuy306,945$311.01$95,462,964.45View SEC Filing  
3/24/2014Charles BakerDirectorSell15,000$302.67$4,540,050.00View SEC Filing  
3/24/2014Sanofimajor shareholderBuy306,945$307.91$94,511,434.95View SEC Filing  
3/21/2014Sanofimajor shareholderBuy305,115$321.22$98,009,040.30View SEC Filing  
3/20/2014Sanofimajor shareholderBuy67,703$328.33$22,228,925.99View SEC Filing  
3/17/2014Michael BrownDirectorSell2,000$334.29$668,580.00View SEC Filing  
3/17/2014Sanofimajor shareholderBuy115,711$328.46$38,006,435.06View SEC Filing  
3/12/2014Sanofimajor shareholderBuy220,995$334.69$73,964,816.55View SEC Filing  
3/11/2014Sanofimajor shareholderBuy380,532$330.41$125,731,578.12View SEC Filing  
3/7/2014Sanofimajor shareholderBuy150,277$328.72$49,399,055.44View SEC Filing  
3/3/2014Sanofimajor shareholderBuy251,594$338.12$85,068,963.28View SEC Filing  
2/27/2014Michael BrownDirectorSell1,000$335.00$335,000.00View SEC Filing  
2/25/2014Joseph GoldsteinDirectorSell1,000$338.86$338,860.00View SEC Filing  
2/25/2014Murray GoldbergSVPSell11,871$339.55$4,030,798.05View SEC Filing  
2/21/2014Alfred GilmanDirectorSell5,000$340.00$1,700,000.00View SEC Filing  
2/21/2014Murray GoldbergSVPSell21,258$336.51$7,153,529.58View SEC Filing  
2/20/2014Joseph GoldsteinDirectorSell1,000$326.99$326,990.00View SEC Filing  
2/18/2014Michael AbermanVPSell3,648$331.42$1,209,020.16View SEC Filing  
2/18/2014Robert TerifaySVPSell12,865$332.68$4,279,928.20View SEC Filing  
2/13/2014Neil StahlSVPSell22,612$318.82$7,209,157.84View SEC Filing  
2/12/2014George YancopoulosInsiderSell88,987$320.33$28,505,205.71View SEC Filing  
2/12/2014Joseph GoldsteinDirectorSell1,000$320.62$320,620.00View SEC Filing  
2/11/2014Alfred GilmanDirectorSell5,000$320.00$1,600,000.00View SEC Filing  
2/11/2014Douglas MccorkleVPSell5,819$325.00$1,891,175.00View SEC Filing  
2/11/2014P Roy VagelosChairmanSell11,475$325.10$3,730,522.50View SEC Filing  
2/7/2014Sanofimajor shareholderBuy168,511$286.78$48,325,584.58View SEC Filing  
2/5/2014Sanofimajor shareholderBuy397,264$284.12$112,870,647.68View SEC Filing  
2/3/2014Sanofimajor shareholderBuy208,972$283.78$59,302,074.16View SEC Filing  
1/28/2014Sanofimajor shareholderBuy157,920$275.90$43,570,128.00View SEC Filing  
1/14/2014Alfred GilmanDirectorSell5,000$300.00$1,500,000.00View SEC Filing  
1/14/2014Douglas MccorkleVPSell4,000$290.00$1,160,000.00View SEC Filing  
1/2/2014Peter PowchikSVPSell20,668$274.77$5,678,946.36View SEC Filing  
12/20/2013Peter PowchikSVPSell9,133$270.21$2,467,827.93View SEC Filing  
11/26/2013George SingDirectorSell10,000$295.00$2,950,000.00View SEC Filing  
11/6/2013Joseph GoldsteinDirectorSell1,000$300.74$300,740.00View SEC Filing  
9/19/2013Leonard SchleiferCEOSell102,949$302.67$31,159,573.83View SEC Filing  
9/19/2013P Roy VagelosChairmanSell145,356$302.86$44,022,518.16View SEC Filing  
9/18/2013Plew Daniel VanSVPSell23,977$303.17$7,269,107.09View SEC Filing  
9/18/2013William RobertsVPSell15,000$304.00$4,560,000.00View SEC Filing  
9/9/2013Leonard S SchleiferCEOSell5,000$275.47$1,377,350.00View SEC Filing  
8/23/2013Joseph GoldsteinDirectorSell1,000$238.29$238,290.00View SEC Filing  
6/10/2013Charles A BakerDirectorSell15,000$251.84$3,777,600.00View SEC Filing  
5/31/2013Arthur F RyanDirectorSell2,500$249.55$623,875.00View SEC Filing  
5/28/2013Joseph L GoldsteinDirectorSell4,000$252.20$1,008,800.00View SEC Filing  
5/21/2013Murray A GoldbergCFOSell66,835$259.74$17,359,722.90View SEC Filing  
5/17/2013Michael S BrownDirectorSell15,000$275.19$4,127,850.00View SEC Filing  
5/14/2013Michael S AbermanVPSell5,529$279.61$1,545,963.69View SEC Filing  
5/13/2013Neil StahlSVPSell23,038$276.88$6,378,761.44View SEC Filing  
5/10/2013George L SingDirectorSell5,000$270.00$1,350,000.00View SEC Filing  
5/8/2013Robert J TerifaySVPSell8,231$261.23$2,150,184.13View SEC Filing  
5/6/2013P Roy VagelosChairmanSell12,018$263.15$3,162,536.70View SEC Filing  
11/27/2012P Roy VagelosChairmanSell64,753$175.22$11,346,020.66View SEC Filing  
11/26/2012Charles A BakerDirectorSell15,000$173.87$2,608,050.00View SEC Filing  
11/14/2012Michael S BrownDirectorSell7,000$147.03$1,029,210.00View SEC Filing  
11/1/2012Arthur F RyanDirectorSell10,000$145.57$1,455,700.00View SEC Filing  
9/6/2012Charles A BakerDirectorSell15,000$150.00$2,250,000.00View SEC Filing  
8/23/2012George L SingDirectorSell10,000$140.50$1,405,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Regeneron Pharmaceuticals (NASDAQ:REGN)
News IconRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) from Biotechnology – Todays Top Gains (NASDAQ:REGN) - October 22 at 11:01 AM
News IconShelton Capital Management Raises Stake in Regeneron ... - DailyQuint (NASDAQ:REGN) - October 21 at 7:02 PM logoRegeneron Pharmaceuticals : Announces Presentation at the 25th Annual Credit Suisse Healthcare Conference (NASDAQ:REGN) - October 21 at 10:33 AM logoRegeneron Announces Presentation at the 25th Annual Credit Suisse Healthcare Conference (NASDAQ:REGN) - October 21 at 10:33 AM
News IconSEC Watch Reporter: Artal Group Sa Increased Holding in Regeneron Pharmaceuticals (Call) (REGN) by $31.41 ... - Chester News (NASDAQ:REGN) - October 19 at 3:38 PM
News IconLive Stock Coverage: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) 2016 Q2 Sentiment Change - Post News (NASDAQ:REGN) - October 19 at 3:38 PM logoRegeneron Pharmaceuticals Inc (NASDAQ:REGN), Teva Pharmaceutical Industries Ltd (NYSE:TEVA) Hit Setback In ... - Market Exclusive (NASDAQ:REGN) - October 19 at 3:38 PM logoRegeneron, Teva Study on Hold by FDA (REGN, TEVA) (NASDAQ:REGN) - October 18 at 6:54 PM
News IconUpdate on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for the day (NASDAQ:REGN) - October 18 at 6:54 PM logoHow These Biotech Stocks are Faring? -- Biogen, Juno Therapeutics ... - PR Newswire (press release) (NASDAQ:REGN) - October 18 at 12:20 PM
News IconThe Statistics Don't Lie: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Earnings Preview - The Voice Registrar (NASDAQ:REGN) - October 18 at 12:20 PM logoStock Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc and Teva Provide Update on Fasinumab Clinical ... - Smarter Analyst (NASDAQ:REGN) - October 18 at 12:20 PM logoWeighing Vertex Pharmaceuticals’ Attributes before It Reports (NASDAQ:REGN) - October 18 at 12:20 PM logoFDA Holds Regeneron, Teva Pain Study (REGN, TEVA) (NASDAQ:REGN) - October 18 at 12:20 PM logoRegeneron, Teva: FDA Places Phase 2b Fasinumab Back Pain Trial On Clinical Hold (NASDAQ:REGN) - October 17 at 12:13 PM
News IconRegeneron Sags With FDA Decisions On Horizon (NASDAQ:REGN) - October 17 at 12:13 PM logoStock Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc and Teva Provide Update on Fasinumab Clinical Development Programs (NASDAQ:REGN) - October 17 at 12:13 PM logoFDA Puts Hold on Regeneron Pain-Drug Study (NASDAQ:REGN) - October 17 at 12:13 PM logoBTIG Analyst Bullish on Ocular Therapeutix Inc (OCUL) Following Strategic Collaboration with Regeneron (NASDAQ:REGN) - October 14 at 6:47 PM logoOcular's (OCUL) Stock Jumps on Collaboration with Regeneron (NASDAQ:REGN) - October 14 at 10:18 AM
News IconHigh Market Cap Stock of the Day – Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) (NASDAQ:REGN) - October 13 at 7:10 PM logo10 Biggest Mid-Day Gainers For Thursday (NASDAQ:REGN) - October 13 at 2:11 PM logoThursday’s Vital Data: Facebook Inc (FB), Citigroup Inc (C) and Regeneron Pharmaceuticals Inc (REGN) (NASDAQ:REGN) - October 13 at 9:58 AM
News IconIn it for the Long Haul: Update on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - CSZ News (NASDAQ:REGN) - October 12 at 6:57 PM logoLegal & General Group Plc Buys A Little More Regeneron Pharmaceuticals, Inc. (REGN) Stock In The Last Quarter (NASDAQ:REGN) - October 12 at 12:28 PM logoCramer: Sing It, Martha -- Nowhere to Run to in This Market, Nowhere to Hide (NASDAQ:REGN) - October 11 at 7:20 PM logoIs Another Blockbuster Drug on the Way for Regeneron Pharmaceuticals, Inc.? - Motley Fool (NASDAQ:REGN) - October 10 at 11:47 AM logoIs Another Blockbuster Drug on the Way for Regeneron Pharmaceuticals, Inc.? (NASDAQ:REGN) - October 10 at 8:29 AM
News IconBroker Roundup For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - The De Soto Edge (NASDAQ:REGN) - October 9 at 11:10 AM logoRegeneron to Report Third Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2016 (NASDAQ:REGN) - October 7 at 12:12 PM logoWill Biogen Join Gilead in the Disappointment Club? (NASDAQ:REGN) - October 7 at 12:12 PM
News IconBrokerage Firm Target Update for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - CSZ News (NASDAQ:REGN) - October 4 at 11:45 AM
News IconStocks Aim To Attain Street Attentions- Regeneron Pharmaceuticals ... - Street Wise Report (press release) (blog) (NASDAQ:REGN) - October 3 at 6:35 PM logoRoth Capital Maintains Regeneron Pharmaceuticals Inc (REGN) At Buy Despite Phase 2 Study Failure - TCC (NASDAQ:REGN) - October 3 at 6:35 PM logoHard To See If Regeneron's Eylea Combo Study Failure Reads Through To Ophthotech's Fovista (NASDAQ:REGN) - October 3 at 6:35 PM logoRegeneron Drug Fails in Combination Trial (REGN) (NASDAQ:REGN) - October 3 at 6:35 PM logoRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Is Expected To Post EPS Of $2.24 - (NASDAQ:REGN) - October 3 at 11:39 AM logoRegeneron: The Amazon Of Biotech? - Seeking Alpha (NASDAQ:REGN) - October 3 at 11:39 AM logoRegeneron's Eylea/Rinucumab Combination Data Disappoints (NASDAQ:REGN) - October 3 at 11:39 AM logoRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Is Expected To Post EPS Of $2.24 (NASDAQ:REGN) - October 2 at 6:03 PM logoRegeneron, Sanofi: Dupixent Phase 3 Atopic Dermatitis Studies Meets Primary Goal (NASDAQ:REGN) - October 2 at 10:58 AM logoWith Shares Trading down at $402.02 Regeneron and Sanofi Announce Positive… (NASDAQ:REGN) - October 1 at 6:09 PM logoRegeneron Pharmaceuticals Inc (REGN) Dips on Drug Data (NASDAQ:REGN) - October 1 at 6:09 PM logo7:01 am Regeneron Pharma announces the phase 2 study of aflibercept co-formulated with rinucumab shows no benefit over aflibercept alone in neovascular age-related macular degeneration (NASDAQ:REGN) - October 1 at 6:09 PM logoRegeneron Announces Phase 2 Study of Aflibercept Co-Formulated ... - PR Newswire (press release) (NASDAQ:REGN) - October 1 at 8:30 AM logoStock Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc Announces Phase 2 Study of Aflibercept Co ... - Smarter Analyst (NASDAQ:REGN) - September 30 at 3:34 PM logoA “Don’t Blink” Opportunity In Regeneron Pharmaceuticals Inc (REGN) (NASDAQ:REGN) - September 30 at 10:12 AM logoA “Don’t Blink” Opportunity In Regeneron Pharmaceuticals Inc (REGN) (NASDAQ:REGN) - September 30 at 9:58 AM logoRegeneron's Eylea combination therapy fails mid-stage study (NASDAQ:REGN) - September 30 at 8:25 AM logoWhy Investors Are Paying a Premium for Regeneron Pharmaceuticals, Inc. - Motley Fool (NASDAQ:REGN) - September 29 at 6:56 PM


Regeneron Pharmaceuticals (NASDAQ:REGN) Chart for Monday, October, 24, 2016

Last Updated on 10/24/2016 by Staff